Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETALs: Nilotinib vs Nilotinib + Peg-IFN in CML
NCT02201459Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Aug 2014
- Primary completion
- Oct 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a in chronic myeloid leukemia (CML), sponsored by Hospices Civils de Lyon. Started Aug 2014; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02201459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201459.